Cerenis Therapeutics and UNTHSC will jointly develop HDL-based pharma products

| By | Drug Development, Innovative Medicines
0
192

Cerenis Therapeutics, an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of oncology and HDL platform technologies, signed a strategic partnership with the University of North Texas Health Science Center.

Therapies focused on increasing HDL (good cholesterol) represent the next frontier in the treatment of cardiovascular disease. Clinical evidence has demonstrated that HDL therapy can rapidly regress atherosclerotic plaque and elevating HDL can reduce cardiovascular morbidity and mortality.

This joint program will focus on the development of new HDL drug delivery products and technologies taking advantage of the unique properties of apoA-I and HDL, nature’s universal molecular targeting delivery system. The joint program entitled the ‘HDL Drug Delivery Initiative’ will leverage the expertise of Cerenis and the research group led by Andras Lacko, PhD, Professor of Physiology and Anatomy at UNT Health Science Center. Dr. Lacko’s research has long focused on the use of nanoparticles to deliver anti-cancer drugs directly to tumors while avoiding damage to healthy cells to spare patients the harmful side effects of chemotherapy. The joint program in HDL research and drug development will bring new products to patients in a diligent and efficient way. The Initiative will be well positioned to become a leading center developing new strategies to address difficult-to-treat patients utilizing a unique HDL nanoparticle platform.

HDL particles as biocompatible adaptive carriers loaded with active agents hold promise to target and selectively kill malignant cells while avoiding healthy ones. A wide variety of drugs can be embedded in these particles targeting markers specific to cancer cells and bring these potent drugs to their intended site of action, with lowered systemic toxicity. Cerenis intends to develop the first HDL-based targeting drug delivery platform dedicated to the oncology market, including immuno-oncology and chemotherapy.

Headquartered in Labege, France, Cerenis Therapeutics focused on the discovery and development of innovative lipid metabolism therapies for the treatment of cardiovascular, metabolic diseases, and HDL targeted drug delivery platform technologies. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess lipids are removed from arteries and transported to the liver for elimination from the body. In addition to advancing HDL technologies for drug delivery, Cerenis is developing a portfolio of lipid metabolism therapies, including HDL mimetics for patients with genetic HDL deficiency, as well as drugs which increase HDL for patients with a low number of HDL particles to treat atherosclerosis and associated metabolic diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).

SOURCE: cerenis
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.